1. 1816 Preliminary safety results from PERUSE, a study of 1436 patients (pts) treated with first-line pertuzumab (P) combined with trastuzumab (H) and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). (September 2015) Authors: Miles, D.; Puglisi, F.; Schneeweiss, A.; Ciruelos, E.; Peretz-Yablonski, T.; Moreno, K.; Restuccia, E.; Lasserre, S.; Bachelot, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC). (September 2015) Authors: Miles, D.; Cameron, D.; Bondarenko, I.; Lyudmila, M.; Alcedo, J.C.; Lopez, R.I.; Im, S.A.; Canon, J.L.; Shparyk, Y.; Yardley, D.; Masuda, N.; Ro, J.; Hubeaux, S.; Quah, C.; Bais, C.; O'Shaughnessy, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S287 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Retrospective Review of the Clinical Outcomes of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Advanced HER2-positive Breast Cancer at the Mount Vernon Cancer Centre. Issue 6 (June 2023) Authors: Bienz, M.; Malek, A.; Sidon, L.; Miles, D. Journal: Clinical oncology Issue: Volume 35:Issue 6(2023) Page Start: e414 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB801 is a potent and selective AXL inhibitor that demonstrates significant anti-tumor activity in combination with standard of care therapeutics. (October 2022) Authors: Paprcka, S.; Sridhar, S.; Goshayeshi, A.; Park, E.; Liu, S.; Flores, R.; Rocha, L.; Miles, D.; Lamani, M.; Cho, S.; Wang, N.; Guan, Y.; Chandrasekar, S.; Kushwaha, R.; Jafri, S.; Kaplan, A.; Stagnaro, E.; Seitz, L.; Kline, J.; Fernandez-Salas, E. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy. (March 2018) Authors: Schindler, U.; Seitz, L.; Ashok, D.; Piovesan, D.; Tan, J.; DiRenzo, D.; Yin, F.; Leleti, M.; Rosen, B.; Miles, D.; Jin, L.; Park, T.; Young, S.; Soriano, F.; Rieger, A.; Karakunnel, J.; Sharif, E.; Powers, J.P.; Walters, M.J. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 1 Page Start: S14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical Trials in Oncology: Are the Results Generalisable?. Issue 6 (June 2015) Authors: Woolf, D.K.; Miles, D.; Nathan, P.; Windmill, E.; Makris, A. Journal: Clinical oncology Issue: Volume 27:Issue 6(2015) Page Start: e14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitor AB801. (October 2022) Authors: Miles, D.; Paprcka, S.; Foley, C.; Qu, S.; Lamani, M.; Paladugu, S.; Huang, H.T.; Tibrewal, N.; Chen, A.; Kulusich, J.; Garrido-Shaqfeh, S.; Fabila, P.; Sridhar, S.; Liu, S.; Swinarski, D.; Zhao, X.; Fernandez-Salas, E.; Green, D.; Jin, L.; Leleti, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors for cancer therapy. (October 2020) Authors: Miles, D.; Chen, Y.; Paprcka, S.L.; Foley, C.N.; Grange, R.; Leleti, M.R.; Zhao, X.; Jin, L.; Young, S.W.; Walters, M.J.; Powers, J.P. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Eligibility for Entry into First Line Metastatic Trials in Patients with Disease Recurrence within 12 Months of Adjuvant Chemotherapy for Early Stage Breast Cancer. Issue 6 (June 2015) Authors: Bhattacharya, I.S.; Hussain, T.; Kadam, M.; Sutherland, S.; Ho, A.; Bernhardt, V.; Ah-See, M.L.; Shah, N.; Ostler, P.; Miles, D.; Makris, A. Journal: Clinical oncology Issue: Volume 27:Issue 6(2015) Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Exploratory biomarker analysis of first-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC) from the phase 2 COLET study. (December 2016) Authors: Wongchenko, M.; Miles, D.; Kim, S.B.; Xu, N.; Amler, L.; Yan, Y.; Simmons, B.; McNally, V.; Brufsky, A. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗